

pUNO3-mcs

Expression vector containing a multiple cloning site and the hygromycin resistance gene

Catalog code: puno3-mcs

For research use only

Version 19F21-MM

PRODUCT INFORMATION

Contents:

- 20 µg of lyophilized plasmid DNA
- 1 ml Hygromycin B Gold at 100 mg/ml

Storage and Stability:

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store Hygromycin B Gold at 4°C or -20°C. The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and full-length ORF sequencing.
- Plasmid DNA was purified by ion exchange chromatography.

GENERAL PRODUCT USE

• **pUNO3-mcs** is a ready-made expression vector containing the hygromycin-resistance gene (*hph*) resistance gene, the hybrid EF1 α /HTLV promoter and a multiple cloning site.

• **pUNO3-mcs** may be used for:

Cloning in a gene of interest. Six unique restriction sites comprise the MCS facilitating cloning of genes. Cloned genes will be under the control of the EF1 α /HTLV promoter.

• As an “empty” control vector, pUNO3-mcs plamids were designed to serve as experimental control vectors for the pUNO3 plasmid family.

METHODS

Plasmid resuspension:

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning:

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5 α .

Hygromycin B usage:

This antibiotic can be used for *E. coli* at 50-100 µg/ml in liquid or solid media and at 50-500 µg/ml to select Hygromycin-resistant mammalian cells.

PLASMID FEATURES

• **EF-1 α / HTLV hybrid promoter** is a composite promoter comprised of the Elongation Factor-1 α (EF-1 α) core promoter¹ and the 5' untranslated region of the Human T-Cell Leukemia Virus (HTLV). EF-1 α utilizes a type 2 promoter that encodes for a «house keeping» gene. It is expressed at high levels in all cell cycles and lower levels during G0 phase. The promoter is also non-tissue specific; it is highly expressed in all cell types. The R segment and part of the U5 sequence (R-U5') of the HTLV Type 1 Long Terminal Repeat² has been coupled to the EF-1 α promoter to enhance stability of DNA and RNA. This modification not only increases steady state transcription, but also significantly increases translation efficiency possibly through mRNA stabilization.

• **MCS:** The multiple cloning site contains the following restriction sites: 5' - SgrAI, SallI, BamHI, Eco47III, NcoI, NheI - 3'

Each restriction site is compatible with many other enzymes, increasing the cloning options.

• **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions, resulting in high levels of steady-state mRNA³.

• **pMB1 ori** is a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **CMV promoter & enhancer** drives the expression of the hygromycin resistance in mammalian cells.

• **Hygro (hygromycin B resistance gene):** Resistance to hygromycin B is conferred by the *hph* gene from *E. coli* which encodes a phosphotransferase. The *hph* gene is driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. Therefore, hygromycin B can be used to select stable mammalian cells transfectants and *E. coli* transformants.

• **Human beta-Globin polyA** is a strong polyadenylation (pAn) signal placed downstream of *hph*. The use of beta-globin pAn minimizes interference⁴ and possible recombination events with the SV40 polyadenylation signal.

1. Kim DW. et al., 1990. Use of the human elongation factor 1 α promoter as a versatile and efficient expression system. Gene 91(2):217-23. 2. Takebe Y. et al., 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72. 3. Carswell S. & Alwine JC., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58. 4. Yu J. & Russell JE., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human β -globin mRNA. Mol Cell Biol. 21(17):5879-88.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



PvuI (7) MfeI (82) EcoNI (96)
SgfI (6)

1 GGATCTGCATCGCTCCGGTCCCCTCAGGGCAGAGCGCACATGCCACAGTCCCAGAAGTTGGGGGAGGGTCGCAATTGAACGGTGCCTA

101 GAGAAGGTGGCGGGGTAACACTGGAAAGTGATGTCGTACTGGCTCCGCTTTCCGAGGGTGGGGAGAACGTATAAGTCAGTAGTCGC

HindIII (245) Bsu36I (291)
Psp1406I (203) PvuII (239) EcoNI (287)
201 GTAACGTTCTTTCGAACGGGTTGCCAGAACACAGCTGAAGCTCGAGGGCTCGATCTCTCCTCACCGCCGCCACTGAGGCC

301 GCCATCCACGCCGGTGGAGTCGCGTCTGCCCTCCGGCTGTGGCCTCTGAACGTCCCGCTAGGTAAAGCTCAGTCAGGAC

NgoMIV (441) XcmI (584)
401 GGGCTTTGTCGGCGTCCCTGGAGCCTACCTAGACTCAGCCGGCTCCACGCTTGCCGACCTGCTCAACTTACGTCTTGTGTT

BamHI (566) PstI (578) NheI (590)
SgrAI (551) SalI (560) Eco47III (572) NcoI (584) Mscl (596)
501 TCTGTTCTGCCGTTACAGATCCAAGCTGTGACCGGGCCCTACCTGAGATCACCGCGTGTGACGGATCCAGCGCTCTGCAGCCATGGCTAGCTGGC

601 CAGACATGATAAGATACTTGTAGAGTTGGACAACACACAACTAGAACATGCACTGAAAAAAATGCTTATTGTGAAATTGTGATGCTATTGCTTATT

HpaI (728) MfeI (739)
701 TGTAAACCATTATAAGCTGCAATAACAAAGTTAACACAAACATTGCAATTCTATTTATGTTCAAGGTTCAAGGGGAGGTGTGGAGGTTAAAGCAAG

801 TAAAACCTCTACAAATGTGGTATGGATTCTAAACAGCATAGCAAACCTTAACCTCAAATCAAGCCTCTACTTGAATCCTTCTGAGGGATGAA

AlwNI (914)
901 TAAGGCATAGGCATCAGGGCTGTTCCAATGTGCATTAGCTGTTGAGCCTCACCTCTTATGGAGTTAACATAGTGTATTCCAAAGGTT

SapI (1006) SspI (1063) SwaI (1077)
1001 GAACTAGCTCTCATTCTTATGTTAAATGCACTGACCTCCACATTCCCTTTAGTAAATTCAGAAATAATTAAATACATCATTGCAATGA

EcoO109I (1138)
1101 AAATAATGTTTTATTAGGCAGAACAGATGCTCAAGGCCCTCATAATATCCCCAGTTAGTAGTTGACTTAGGAACAAAGAACCTTAATA

ScaI (1295)
1201 GAAATTGGACAGCAAGAAAGCGAGCTCTAGCGAATTCTCGACTCATTCTTGCCTCGACGAGTGTGGCGTGGTCCACTATCGCGAGTAC

342 E K A R P R T S P R R N G S D A L V

1301 TTCTACACAGCCATCGGTCCAGACGGCCGGCTCTGGGGCGATTGTGACGCCAGTCCCGGCTCGGATCGGACGATTGCGTCATCGACCC

323 E V C G D T W V A A S R R A I Q T R G V T G A G S R V I A D C R G

SacII (1486)
1401 TGCGCCAAGCTGCATCATGAAATTGCCGTCAACCAAGCTCTGATAGAGTTGGCAAGACCAATGCGGAGCATATGCCGGAGCCGCGATCCG

289 Q A W A A D D F N G D V L S Q Y L Q D L G I R L M Y A R L R P S G A

BsrBI (1516)
1501 CAAGCTCCGGATGCCCTCGCTCGAAGTAGCCGTCTGCTGCTCCATACAAGCCAACACGGCTCCAGAAGAAAGATGTTGGACCTCGTATTGGAAATC

256 L E P H R R E F Y R T Q Q E M C A L W P R W F F I N A V E Y Q S D

DraIII (1684)
BstAPI (1683)
1601 CCCGAACATGCCCTCGCTCCAGTCATGACCGCTGTTATGCCGCATTGCCGTCAAGGACATTGTTGGAGCCAAATCCGGTGACGGGGCCGACT

223 G F M A E S W D I V A T I R G N D T L V N N S G F D A H V L H R V

Tth111I (1759)
1701 TCGGGCAGTCTGGCCCAAAGCATCAGCTCATCGAGAGCCTGCGCGACGGACACTGACGGTGTCTCCATCACAGTTGCCAGTGTACACATGGG

189 E P C D E A W L M L E D L A Q A V S A S V T D D M V T Q W H Y V H P

NdeI (1814)
1801 GATCAGCAATCGCGCATATGAAATCACGCATGTAGTAGTATTGACCGATTCCCTGGCTCGAATGGGCGAACCCGCTGCTGGCTAACATCGGCCG

156 D A I A C I F D R W T T Y Q G I G Q P G F P G F G S T Q S L D A A

PvuI (1902)
SgfI (1901) SacI (1915)
1901 AGCGATCGCATCATGAGCTCCGCACGGGTTGCAGAACAGCGGGCAGTCGGTTCAAGGAGCTTGCACACCTGTGCACGGGGAGATG

123 A I A D M L E A V P Q L V A P L E T E P L D Q L T V G Q A R R S I

2001 CAATAGGTCAAGGCTCTCGCTGAATTCCCAATGTCAAGCACTTCCGGAATCGGGAGCGCGCCGATGCAAAGTGCCGATAAACATAACGATCTTGAGA

89 C Y T L S E S F E G I D L V E P I P L A A S A F H R Y V Y R D K Y F

2101 AACCATCGGCAGCTATTACCCGAGACATTCACGCCCTCCTACATCGAAGCTGAAAGCACGAGATTCTCGCCCTCCGAGAGCTGCTACAGGTC

56 G D A C S N V R L V Y G R G G V D F S F A R S E E G E S L Q M L D

PshAI (2236)
Tth111I (2203)
2201 GGAGACGCTGCAACTTTCGATCAGAAACTTCGCGACAGACGTCGCGGTGAGTTCAAGGCTTTCTAGATGCCCTCTATAGTGAGTCGTTTAC

23 S V S D F K E I L F K A V S T A T L E P K K M ←

AseI (2323)
 2301 TATGCCGATATACTATGCCGATGATTAATTGTCAAACAGCGTGGATGGCGTCTCCAGCTTATCTGACGGTTACTAAACGAGCTGTGCTTATATAGACC

SpeI (2478)
 2401 TCCCACCGTACACGCCCTACCGCCCCATTGCGTCAATGGGGCGGAGTTGTTACGACATTTGAAAGTCCCGTTGATTTA**TAG**CAAAACAAACTCCCAT

SnaBI (2606)
 2601 GACTAATACGTAGATGACTGCCAAGTAGGAAAGTCCCATAAGGTATGACTGGGCATAATGCCAGGCAGGGCATTGACGTCAATAGGG

NdeI (2711)
 2701 GGGTACTTGGCATATGATACACTTGATGACTGCCAAGTGGCAGTTACCGTAAACTCCACCCATTGACGTCAATGAAAGTCCATTGGCGTTA

PacI (2897)
 2801 CTATGGGAACATACGTATTGACGTCAATGGGGGGGGCGTGGCGGTAGCCAGGCCATTACCGTAAGTTATGTAACGCCCTGCAGGTTA

BspLU11I (2907)
 2901 ATTAAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCCGTTGCTGGCTTTCCATAGGCTCCGCCCCCTGACGAGCATC

 3001 ACAAAAATCGACGCTCAAGTCAGAGGTGGCAAACCCGACAGGACTATAAGATACCAGGCCTTCCCTGGAAAGCGTGGCTTCTAGCTCACGCTGTAGGTATCTCAGTTGGTAGGTC

 3101 GACCTGCCCTTACCGATACTGTCGCCCTTCTCCCTGGAAAGCGTGGCTTCTAGCTCACGCTGTAGGTATCTCAGTTGGTAGGTC

 3201 GTTCGCTCCAAGCTGGCTGTGACGAACCCCCGTTAGCCGACCGCTGCCCTATCCGTAACTATCGCTTGAGTCAACCCGTAAGACACG

AlwNI (3318)
 3301 ACTTATGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGAGCGGTGCTACAGAGTTCTGAAGTGGTGGCTAACTACGGCTA

 3401 CACTAGAAGAACAGTATTGGTATCTGCCTCTGCTGAAGCCAGTTACCTCGGAAAAAGAGTTGGTAGCTTGTACCGCAAACAAACCCGCTGGT

 3501 AGCGGTGGTTTTTTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTGATCTTCTACGGGTCTGACGCTCAGTGG

PacI (3637) SwaI (3646) NotI (3656)
 3601 ACGAAAACTCACGTTAAGGGATTTGGTATGGCTAGTTA**ATTAAACATTAAATCAGCGGCCGAAATAAAATATCTTATTT**CATTACATCTGTGTGTT

 3701 GGTTTTTGTGTAATCGTAACATACGCTCTCCATCAAACAAACGAAACAAACAAACTAGCAAATAGGCTGTCCCAGTGCAAGTGCAGGTG
 3801 CCAGAACATTCTATCGAA